Evidence mapPaperPMID 41878133Full record

ReviewInternational journal of nanomedicine2026

Research Progress on Nano-Drug Delivery Systems for Photothermal Cancer Therapy.

Tao Li, Dan Xiao, Yanlong Yin, Liwen Hu

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tao LiDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Dan XiaoDepartment of Pharmacy, Jiu Xing Nephrotic Hospital of Chengdu Wuhou, Chengdu, People's Republic of China.
Yanlong YinDepartment of Pharmacy, Jinniu District Hospital of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Liwen HuDepartment of Research and Development, Sichuan Baili Pharmaceutical Co., Ltd, Chengdu, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains one of the most formidable challenges in modern medicine. To mitigate the systemic toxicity associated with conventional therapies such as radiotherapy and chemotherapy, photothermal therapy (PTT) has emerged as a highly promising adjuvant modality. The efficacy of PTT hinges on photothermal agents (PTAs), typically nanomaterials that convert light energy into localized hyperthermia to ablate cancer cells. The convergence of nanotechnology and drug delivery has provided a robust platform for PTT, enabling its integration with other therapeutic modalities to enhance efficacy and reduce side effects. This review constructs a three-dimensional analytical framework based on the "carrier-function-application" paradigm, systematically evaluating four major nanocarrier families: lipids, polymers, proteins, and biomimetics. We critically analyze the unique advantages and challenges of each carrier type when delivering various PTAs and further explore multimodal combination therapy strategies. By synthesizing cutting-edge research, we distill key design principles: the core of an efficient photothermal nanosystem lies in overcoming bottlenecks such as poor tumor targeting and heterogeneous tumor microenvironments through intelligent responsive design and biomimetic modification. This framework provides a clear theoretical basis and practical pathway for developing next-generation PTT platforms characterized by high efficiency, safety, and strong clinical translation potential.

Indexed as

Hyperthermia, InducedNanoparticle Drug Delivery SystemNeoplasmsPhotothermal TherapyAnimalsAntineoplastic AgentsCombined Modality TherapyHumansNanomedicineAntineoplastic AgentsNanoparticle Drug Delivery Systemcancer therapycombination therapydrug deliveryphotothermal therapy

Identifiers

PMID41878133
PMCPMC13007971

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.